High Legume, Soy Intake Linked to Lower Risk for Hypertension
Medically reviewed by Drugs.com
via HealthDayFRIDAY, May 8, 2026 -- High legume and soy consumption is associated with a lower risk for hypertension, according to a review and meta-analysis published online May 7 in BMJ Nutrition Prevention & Health.
Michael Metoudi, R.D., from Plant-Based Health Professionals UK in London, and colleagues conducted a systematic review and meta-analysis to examine the association between legume and soy consumption and the risk for hypertension. The meta-analysis included 12 prospective studies.
The researchers found that the summary relative risk for hypertension in association with high versus low intake was 0.84 and 0.81 for legumes and soy, respectively. The summary relative risk per 100 g/day was 0.88 and 0.76 for legumes and soy, respectively, in the linear dose-response analyses. For legumes, the test for nonlinearity was not significant, suggesting a linear reduction in risk up to about 170 g/day; there was indication of nonlinearity for soy, with most of the reduction in risk seen up to intake of about 60 to 80 g/day. For legumes, there was an indication of publication bias with Egger's test, but two outlying studies explained this finding. The likelihood of causality was considered probable for legumes and soy in relation to hypertension risk using World Cancer Research Fund criteria.
"Although further large-scale cohorts are needed for confirmation, these findings provide further evidence in support of dietary recommendations to the public to prioritize and integrate legumes and soy foods as healthy protein sources in the diet," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-05-09 02:11
Read more
- 2014 to 2023 Saw Rise in Pediatric PCP Visits With Mental Health Issues
- Partner Therapeutics Announces Receipt of FDA Commissioner’s National Priority Voucher for Bizengri (zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma
- Too Little or Too Much Sleep Ages Every Organ in Your Body
- Sleep and Anxiety Medications in Pregnancy Appear to Pose Little Harm
- Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Update on FDA Advisory Committee Vote on Camizestrant in Combination with a CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions